Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Next Previous
Trial Profile

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emactuzumab (Primary)
  • Indications Giant cell tumour of tendon sheath
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGENT
  • Sponsors SynOx Therapeutics

Most Recent Events

  • 05 Aug 2025 According to a SynOx Therapeutics media release, enrollment has been completed in this trial and top-line data from the study in the first quarter of 2026.
  • 31 Jul 2025 Status changed from recruiting to active, no longer recruiting.
  • 30 Oct 2024 According to a SynOx Therapeutics media release, the company adds new investor and capital to series B financing, raising total to $92 Million.Proceeds from the financing are supporting a registrational Phase 3 clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top